The Intrauterine Device: How to Deploy This Strategy in the Molecular World?
Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073.
Authors
- Claire F. Friedman (ORCID: https://orcid.org/0000-0003-2621-8553)
- Paul M. Johannet (ORCID: https://orcid.org/0000-0002-9264-8327)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2034
- Primary Topic
- Reproductive System and Pregnancy
- Type
- article
- Field-Weighted Citation Impact
- 0.00